RCUS catalyst calendar

Arcus Biosciences, Inc.

Upcoming catalysts
9
Cash runway
15.3 months
Cash & investments
$702M
Phase 3 programs
3

Arcus Biosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 9 upcoming events on record.

Cash runway is approximately 15.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 24 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants Trial Milestone Phase 1
January 15, 2027 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies Trial Milestone Phase 2
May 15, 2027 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer Trial Milestone Phase 2
May 15, 2027 Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function Trial Milestone Phase 1
September 15, 2027 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Trial Milestone Phase 1
April 15, 2028 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Trial Milestone Phase 3
March 15, 2029 A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors Trial Milestone Phase 1
November 30, 2030 Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Trial Milestone Phase 3

Track RCUS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open RCUS in the tracker

Recent history

DateEventTypePhase
August 28, 2026 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body Trial Milestone Phase 3
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 21, 2026 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Trial Milestone Phase 1
July 3, 2026 A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants Trial Milestone Phase 1
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 29, 2026 A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies Trial Milestone Phase 1
April 20, 2026 8-K filed: Other event Filing —
April 6, 2026 Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) Trial Milestone Phase 1
March 23, 2026 8-K filed: Leadership change Corporate —
February 25, 2026 Quarterly results filed (8-K) Earnings —
December 18, 2025 8-K filed: Material agreement Corporate —
December 12, 2025 8-K filed: Other event Filing —
November 3, 2025 8-K filed: Other event Filing —
October 28, 2025 Quarterly results filed (8-K) Earnings —
October 18, 2025 Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) Trial Milestone Phase 1
October 14, 2025 8-K filed: Other event Filing —
October 6, 2025 8-K filed: Other event Filing —
September 5, 2025 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. Trial Milestone Phase 1/Phase 2
August 25, 2025 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies Trial Milestone Phase 1
August 6, 2025 Quarterly results filed (8-K) Earnings —
July 9, 2025 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Trial Milestone Phase 2
June 12, 2025 8-K filed: Other event Filing —
June 2, 2025 8-K filed: Reg FD disclosure, Other event Filing —
May 6, 2025 Quarterly results filed (8-K) Earnings —
January 23, 2025 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Trial Milestone Phase 1
November 18, 2024 A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Trial Milestone Phase 1
August 30, 2024 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Trial Milestone Phase 1/Phase 2
June 17, 2024 Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors Trial Milestone Phase 1
February 23, 2024 A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers Trial Milestone Phase 1
October 31, 2023 A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.